




Instance: composition-en-eb26fa1671149a9a84afe4c1bb85528a
InstanceOf: CompositionUvEpi
Title: "Composition for tecfidera Package Leaflet"
Description:  "Composition for tecfidera Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mpeb26fa1671149a9a84afe4c1bb85528a)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - tecfidera"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What is in this leaflet</p>
<ol>
<li>What Tecfidera is and what it is used for  </li>
<li>What you need to know before you take Tecfidera  </li>
<li>How to take Tecfidera </li>
<li>Possible side effects  </li>
<li>How to store Tecfidera  </li>
<li>Contents of the pack and other information </li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What tecfidera is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What tecfidera is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What Tecfidera is </p>
<p>Tecfidera is a medicine that contains the active substance dimethyl fumarate. </p>
<p>What Tecfidera is used for </p>
<p>Tecfidera is used to treat relapsing-remitting multiple sclerosis (MS) in patients aged 13 years 
and older.  </p>
<p>MS is a long-term condition that affects the central nervous system (CNS), including the brain and the 
spinal cord. Relapsing-remitting MS is characterised by repeated attacks (relapses) of nervous system 
symptoms. Symptoms vary from patient to patient, but typically include walking difficulties, feeling 
off balance and visual difficulties (e.g. blurred or double vision). These symptoms may disappear 
completely when the relapse is over, but some problems may remain. </p>
<p>How Tecfidera works </p>
<p>Tecfidera seems to work by stopping the body s defence system from damaging your brain and spinal 
cord. This may also help to delay future worsening of your MS.  </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take tecfidera"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take tecfidera"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Do not take Tecfidera </p>
<ul>
<li>if you are allergic to dimethyl fumarate or any of the other ingredients of this medicine (listed 
in section 6). </li>
<li>if you are suspected to suffer from a rare brain infection called progressive multifocal 
leukoencephalopathy (PML) or if PML has been confirmed. </li>
</ul>
<p>Warnings and precautions </p>
<p>Tecfidera may affect your white blood cell counts, your kidneys and liver. Before you start 
Tecfidera, your doctor will do a blood test to count the number of your white blood cells and will 
check that your kidneys and liver are working properly. Your doctor will test these periodically during 
treatment. If your number of white blood cells decreases during treatment, your doctor may consider 
additional tests or discontinue your treatment. </p>
<p>Talk to your doctor before taking Tecfidera if you have:</p>
<ul>
<li>severe kidney disease </li>
<li>severe liver disease </li>
<li>a disease of the stomach or bowel </li>
<li>a serious infection (such as pneumonia) </li>
</ul>
<p>Herpes zoster (shingles) may occur with Tecfidera treatment. In some cases, serious complications 
have occurred. You should inform your doctor immediately if you suspect you have any symptoms 
of shingles. </p>
<p>If you believe your MS is getting worse (e.g. weakness or visual changes) or if you notice any new 
symptoms, talk to your doctor straight away because these may be the symptoms of a rare brain 
infection called PML. PML is a serious condition that may lead to severe disability or death. </p>
<p>A rare but serious kidney disorder called Fanconi syndrome has been reported with a medicine 
containing dimethyl fumarate, in combination with other fumaric acid esters, used to treat psoriasis (a 
skin disease). If you notice you are passing more urine, are thirstier and drinking more than normal, 
your muscles seem weaker, you break a bone, or just have aches and pains, talk to your doctor as soon 
as possible so that this can be investigated further. </p>
<p>Children and adolescents </p>
<p>Do not give this medicine to children below 10 years of age because no data are available in this age 
group. </p>
<p>Other medicines and Tecfidera </p>
<p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other 
medicines, in particular:</p>
<ul>
<li>medicines that contain fumaric acid esters (fumarates) used to treat psoriasis; </li>
<li>medicines that affect the body s immune system including chemotherapy, 
immunosuppressants, or other medicines used to treat MS; </li>
<li>medicines that affect the kidneys including some antibiotics (used to treat infections),  water 
tablets  (diuretics), certain types of painkillers (such as ibuprofen and other similar anti-
inflammatories and medicines purchased without a doctor s prescription) and medicines that 
contain lithium;  </li>
<li>taking Tecfidera with certain types of vaccines (live vaccines) may cause you to get an infection 
and should, therefore, be avoided. Your doctor will advise whether other types of vaccines (non-
live vaccines) should be given.  </li>
</ul>
<p>Tecfidera with alcohol </p>
<p>Consumption of more than a small amount (more than 50 ml) of strong alcoholic drinks (more than 
30% alcohol by volume, e.g. spirits) should be avoided within an hour of taking Tecfidera, as alcohol 
can interact with this medicine. This could cause inflammation of the stomach (gastritis), especially in 
people already prone to gastritis. 
Pregnancy and breast-feeding  </p>
<p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask 
your doctor or pharmacist for advice before taking this medicine. </p>
<p>Pregnancy </p>
<p>There is limited information about the effects of this medicine on the unborn child if used during 
pregnancy. Do not use Tecfidera if you are pregnant unless you have discussed this with your doctor 
and this medicine is clearly necessary for you. </p>
<p>Breast-feeding </p>
<p>It is not known whether the active substance of Tecfidera passes into breast milk. Your doctor will 
advise whether you should stop breast-feeding, or stop using Tecfidera. This involves balancing the 
benefit of breast-feeding for your child, and the benefit of therapy for you. </p>
<p>Driving and using machines </p>
<p>Tecfidera is not expected to affect your ability to drive and use machines. </p>
<p>Tecfidera contains sodium </p>
<p>This medicine contains less than 1 mmol sodium (23 mg) per capsule, that is to say essentially 
 sodium free . </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take tecfidera"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take tecfidera"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Always take this medicine exactly as your doctor has told you. Check with your doctor if you are not 
sure. </p>
<p>Starting dose: 120 mg twice a day. 
Take this starting dose for the first 7 days, then take the regular dose.  </p>
<p>Regular dose: 240 mg twice a day. </p>
<p>Tecfidera is for oral use. </p>
<p>Swallow each capsule whole, with some water. Do not divide, crush, dissolve, suck or chew the 
capsule as this may increase some side effects. </p>
<p>Take Tecfidera with food   it may help to reduce some of the very common side effects (listed in 
section 4). </p>
<p>If you take more Tecfidera than you should </p>
<p>If you have taken too many capsules, talk to your doctor straight away. You may experience side 
effects similar to those described below in section 4. If you forget to take Tecfidera </p>
<p>If you forget or miss a dose, do not take a double dose.  </p>
<p>You may take the missed dose if you leave at least 4 hours between the doses. Otherwise wait until 
your next planned dose.<br />
If you have any further questions on the use of this medicine, ask your doctor or pharmacist. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. </p>
<p>Serious side effects </p>
<p>Tecfidera may lower lymphocyte counts (a type of white blood cell). Having a low white blood cell 
count can increase your risk of infection, including the risk of a rare brain infection called progressive 
multifocal leukoencephalopathy (PML). PML may lead to severe disability or death. PML has 
occurred after 1 to 5 years of treatment and so your physician should continue to monitor your white 
blood cells throughout your treatment, and you should remain observant of any potential symptoms of 
PML as described below. The risk of PML may be higher if you have previously taken a medicine 
impairing the functionality of your body s immune system. </p>
<p>The symptoms of PML may be similar to an MS relapse. Symptoms may include new or worsening 
weakness on one side of the body; clumsiness; changes in vision, thinking, or memory; or confusion or 
personality changes, or speech and communication difficulties lasting for more than several days. 
Therefore, if you believe your MS is getting worse or if you notice any new symptoms while you are 
on Tecfidera treatment, it is very important that you speak to your doctor as soon as possible. Also 
speak with your partner or caregivers and inform them about your treatment. Symptoms might arise 
that you might not become aware of by yourself. </p>
<p>Call your doctor straight away if you experience any of these symptoms  </p>
<p>Severe allergic reactions </p>
<p>The frequency of severe allergic reactions cannot be estimated from the available data (not known).  </p>
<p>Reddening of the face or body (flushing) is a very common side effect. However, should flushing be 
accompanied by a red rash or hives and you get any of these symptoms:</p>
<ul>
<li>swelling of the face, lips, mouth or tongue (angioedema) </li>
<li>wheezing, difficulty breathing or shortness of breath (dyspnoea, hypoxia) </li>
<li>dizziness or loss of consciousness (hypotension) </li>
</ul>
<p>then this may represent a severe allergic reaction (anaphylaxis). </p>
<p>Stop taking Tecfidera and call a doctor straight away </p>
<p>Other side effects </p>
<p>Very common (may affect more than 1 in 10 people) 
- reddening of the face or body feeling warm, hot, burning or itchy (flushing) 
- loose stools (diarrhoea) 
- feeling sick (nausea)<br />
- stomach pain or stomach cramps </p>
<p>Taking your medicine with food can help to reduce the side effects above </p>
<p>Substances called ketones, which are naturally produced in the body, very commonly show up in urine 
tests while taking Tecfidera. </p>
<p>Talk to your doctor about how to manage these side effects. Your doctor may reduce your dose. Do 
not reduce your dose unless your doctor tells you to. </p>
<p>Common (may affect up to 1 in 10 people) 
- inflammation of the lining of the intestines (gastroenteritis) 
- being sick (vomiting) 
- indigestion (dyspepsia) 
- inflammation of the lining of the stomach (gastritis) 
- gastrointestinal disorder 
- burning sensation 
- hot flush, feeling hot 
- itchy skin (pruritus) 
- rash 
- pink or red blotches on the skin (erythema) 
- hair loss (alopecia) </p>
<p>Side effects which may show up in your blood or urine tests 
- low levels of white blood cells (lymphopenia, leucopenia) in the blood. Reduced white blood 
cells could mean your body is less able to fight an infection. If you have a serious infection 
(such as pneumonia), talk to your doctor immediately 
- proteins (albumin) in urine 
- increase in levels of liver enzymes (ALT, AST) in the blood </p>
<p>Uncommon (may affect up to 1 in 100 people) 
- allergic reactions (hypersensitivity) 
- reduction in blood platelets </p>
<p>Not known (frequency cannot be estimated from the available data) 
- liver inflammation and increase in levels of liver enzymes (ALT or AST in combination with 
bilirubin) 
- herpes zoster (shingles) with symptoms such as blisters, burning, itching or pain of the skin, 
typically on one side of the upper body or the face, and other symptoms, like fever and 
weakness in the early stages of infection, followed by numbness, itching or red patches with 
severe pain 
- runny nose (rhinorrhoea) </p>
<p>Children (13 years of age and above) and adolescents 
The side effects listed above also apply to children and adolescents.<br />
Some side effects were reported more frequently in children and adolescents than in adults, e.g, 
headache, stomach pain or stomach cramps, being sick (vomiting), throat pain, cough, and painful 
menstrual periods. </p>
<p>Reporting of side effects 
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects 
not listed in this leaflet. You can also report side effects directly via the national reporting system 
listed in Appendix V. By reporting side effects you can help provide more information on the safety of 
this medicine. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store tecfidera"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store tecfidera"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Keep this medicine out of the sight and reach of children. </p>
<p>Do not use this medicine after the expiry date which is stated on the blister and the carton after  EXP . 
The expiry date refers to the last day of that month. </p>
<p>Do not store above 30 C. 
Keep the blisters in the outer carton in order to protect from light. 
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to 
dispose of medicines you no longer use. These measures will help protect the environment. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What Tecfidera contains  </p>
<p>The active substance is dimethyl fumarate.<br />
Tecfidera 120 mg: Each capsule contains 120 mg of dimethyl fumarate. 
Tecfidera 240 mg: Each capsule contains 240 mg of dimethyl fumarate. </p>
<p>The other ingredients are microcrystalline cellulose, croscarmellose sodium, talc, silica colloidal 
anhydrous, magnesium stearate, triethyl citrate, methacrylic acid   methyl methacrylate copolymer 
(1:1), methacrylic acid   ethyl acrylate copolymer (1:1) dispersion 30%, simeticone, sodium 
laurilsulfate, polysorbate 80, gelatin, titanium dioxide (E171), brilliant blue FCF (E133), yellow iron 
oxide (E172), shellac, potassium hydroxide and black iron oxide (E172). </p>
<p>What Tecfidera looks like and contents of the pack </p>
<p>Tecfidera 120 mg gastro-resistant hard capsules are green and white and printed with  BG-12 120 mg<br />
and are available in packs containing 14 capsules. </p>
<p>Tecfidera 240 mg gastro-resistant hard capsules are green and printed with  BG-12 240 mg  and are 
available in packs containing 56 or 168 capsules.  </p>
<p>Not all pack sizes may be marketed. </p>
<p>Marketing Authorisation Holder </p>
<p>Biogen Netherlands B.V. 
Prins Mauritslaan 1171 LP Badhoevedorp 
The Netherlands </p>
<p>Manufacturer </p>
<p>FUJIFILM Diosynth Biotechnologies Denmark ApS 
Biotek All  1 
DK-3400 Hiller d 
Denmark  </p>
<p>Biogen Netherlands B.V. 
Prins Mauritslaan 1171 LP Badhoevedorp 
The Netherlands </p>
<p>For any information about this medicine, please contact the local representative of the Marketing 
Authorisation Holder </p>
<p>Belgi /Belgique/Belgien 
Biogen Belgium NV/SA 
T l/Tel: +32 2 2191Lietuva 
Biogen Lithuania UAB 
Tel: +370 5 259 6  </p>
<p>Te : +359 2 962 12 Luxembourg/Luxemburg 
Biogen Belgium NV/SA 
T l/Tel: +32 2 2191 esk  republika 
Biogen (Czech Republic) s.r.o. 
Tel: +420 255 706 Magyarorsz g 
Biogen Hungary Kft. 
Tel: + 36 1 899 9Danmark 
Biogen (Denmark) A/S 
Tlf: +45 77 41 57 Malta 
Pharma. MT Ltd.<br />
Tel: +356 21337Deutschland 
Biogen GmbH 
Tel: +49 (0) 89 99 6Nederland 
Biogen Netherlands B.V. 
Tel: +31 20 542 2Eesti 
Biogen Estonia O<br />
Tel: +372 618 9Norge 
Biogen Norway AS 
Tlf: +47 23 40 01 <br />
Genesis Pharma SA<br />
T : +30 210 8771 sterreich 
Biogen Austria GmbH 
Tel: +43 1 484 46 Espa a 
Biogen Spain, S.L. 
Tel: +34 91 310 7Polska 
Biogen Poland Sp. z o.o.<br />
Tel: +48 22 351 51 France 
Biogen France SAS 
T l: +33 (0)1 41 37 95 Portugal 
Biogen Portugal Sociedade Farmac utica, 
Unipessoal, Lda. 
Tel: +351 21 318 8Hrvatska 
Biogen Pharma d.o.o<br />
Tel: +385 (0) 1 775 73 Rom nia 
Johnson &amp; Johnson Romania S.R.L.<br />
Tel: +40 21 207 18 Ireland 
Biogen Idec (Ireland) Ltd. 
Tel: +353 (0)1 463 7Slovenija 
Biogen Pharma d.o.o. 
Tel: +386 1 511 02  sland 
Icepharma hf 
S mi: +354 540 8Slovensk  republika 
Biogen Slovakia s.r.o. 
Tel: +421 2 323 340 Italia 
Biogen Italia s.r.l. 
Tel: +39 02 5849Suomi/Finland 
Biogen Finland Oy 
Puh/Tel: +358 207 401 <br />
Genesis Pharma Cyprus Ltd<br />
T : +3572 2 765Sverige 
Biogen Sweden AB 
Tel: +46 8 594 113 Latvija 
Biogen Latvia SIA 
Tel: +371 68 688 United Kingdom (Northern Ireland) 
Biogen Idec (Ireland) Limited 
Tel: +44 (0) 1628 50 1This leaflet was last revised in {MM YYYY}. </p>
<p>Detailed information on this medicine is available on the European Medicines Agency web site: </p>         </div>"""      



Instance: composition-da-eb26fa1671149a9a84afe4c1bb85528a
InstanceOf: CompositionUvEpi
Title: "Composition for tecfidera Package Leaflet"
Description:  "Composition for tecfidera Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mpeb26fa1671149a9a84afe4c1bb85528a)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - tecfidera"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #da
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Oversigt over indlægssedlen </p>
<ol>
<li>Virkning og anvendelse </li>
<li>Det skal du vide, før du begynder at tage Tecfidera </li>
<li>Sådan skal du tage Tecfidera </li>
<li>Bivirkninger </li>
<li>Opbevaring </li>
<li>Pakningsstørrelser og yderligere oplysninger </li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What tecfidera is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What tecfidera is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Hvad Tecfidera er </p>
<p>Tecfidera er et lægemiddel, der indeholder det aktive stof dimethylfumarat. </p>
<p>Hvad Tecfidera anvendes til </p>
<p>Tecfidera anvendes til behandling af attakvis remitterende multipel sklerose (MS) hos patienter 
i alderen 13 år og derover. </p>
<p>MS er en kronisk sygdom, der påvirker centralnervesystemet (CNS), herunder hjernen og rygmarven. 
Attakvis remitterende MS er kendetegnet ved gentagne attakker (tilbagefald) af symptomer fra 
nervesystemet. Symptomerne varierer fra patient til patient, men omfatter typisk gangbesvær, 
balanceproblemer og synsforstyrrelser (f.eks. sløret syn eller dobbeltsyn). Disse symptomer kan 
forsvinde helt, når tilbagefaldet er overstået, men nogle gener kan vare ved. </p>
<p>Sådan virker Tecfidera </p>
<p>Tecfidera lader til at virke ved at forhindre kroppens forsvarssystem i at skade din hjerne og rygmarv. 
Dette kan også hjælpe med til at forsinke fremtidig forværring af MS. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take tecfidera"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take tecfidera"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag ikke Tecfidera </p>
<ul>
<li>hvis du er allergisk over for dimethylfumarat eller et af de øvrige indholdsstoffer i Tecfidera 
(angivet i punkt 6). </li>
<li>hvis der er formodning om, at du lider af en sjælden hjerneinfektion kaldet progressiv 
multifokal leukoencefalopati (PML), eller hvis PML er blevet bekræftet. </li>
</ul>
<p>Advarsler og forsigtighedsregler </p>
<p>Tecfidera kan påvirke antallet af hvide blodlegemer, dine nyrer og din lever. Inden du starter med at 
tage Tecfidera, vil din læge tage en blodprøve og bestemme antallet af hvide blodlegemer i dit blod 
samt kontrollere, at dine nyrer og din lever fungerer korrekt. Din læge vil tage disse blodprøver 
regelmæssigt under behandlingen. Hvis antallet af dine hvide blodlegemer falder under behandlingen, 
vil din læge muligvis overveje yderligere tests eller afbryde behandlingen. </p>
<p>Kontakt lægen, før du tager Tecfidera, hvis du har:</p>
<ul>
<li>en alvorlig nyresygdom </li>
<li>en alvorlig leversygdom </li>
<li>en sygdom i maven eller tarmsystemet </li>
<li>en alvorlig infektion (såsom lungebetændelse) </li>
</ul>
<p>Herpes zoster (helvedesild) kan forekomme ved behandling med Tecfidera. I visse tilfælde er der 
forekommet alvorlige komplikationer. Du skal omgående informere lægen, hvis du har mistanke 
om, at du har symptomer på helvedesild. </p>
<p>Hvis du mener, at din MS bliver værre (f.eks. svaghed eller synsændringer), eller hvis du bemærker 
nye symptomer, skal du straks tale med din læge, da dette kan være symptomer på en sjælden 
hjerneinfektion kaldet PML. PML er en alvorlig lidelse, der kan resultere i svær invaliditet eller død. </p>
<p>En sjælden, men alvorlig nyresygdom kaldet Fanconis syndrom er blevet indberettet med et 
lægemiddel indeholdende dimethylfumarat i kombination med andre fumarsyreestere anvendt til 
behandling af psoriasis (en hudsygdom). Hvis du bemærker, at du tisser mere, er mere tørstig og 
drikker mere end normalt, at dine muskler virker svagere, du brækker en knogle eller blot har ømhed 
og smerter, skal du kontakte lægen hurtigst muligt, så det kan blive undersøgt nærmere. </p>
<p>Børn og unge </p>
<p>Giv ikke dette lægemiddel til børn under 10 år, da der ikke foreligger nogen data for denne 
aldersgruppe. </p>
<p>Brug af andre lægemidler sammen med Tecfidera </p>
<p>Fortæl altid lægen eller apotekspersonalet, hvis du tager andre lægemidler, for nylig har taget andre 
lægemidler eller planlægger at tage andre lægemidler. Oplys især, hvis du tager følgende:</p>
<ul>
<li>lægemidler, der indeholder fumarsyreestere (fumarater), som anvendes til behandling af 
psoriasis; </li>
<li>lægemidler, der påvirker kroppens immunsystem, herunder kemoterapi, 
immunundertrykkende lægemidler eller andre lægemidler, der anvendes til behandling af 
MS; </li>
<li>lægemidler, der påvirker nyrerne, herunder nogle antibiotika (til behandling af infektioner), 
vanddrivende lægemidler (diuretika), visse typer smertestillende lægemidler (såsom 
ibuprofen og andre lignende lægemidler mod gigt og lægemidler, som købes uden recept) og 
lægemidler, der indeholder lithium; </li>
<li>vaccination med visse typer vacciner (levende, svækkede vacciner) under behandling med 
Tecfidera kan forårsage, at du får en infektion, og skal derfor undgås. Din læge vil rådgive dig 
om, hvorvidt andre typer vacciner (ikke-levende vacciner) skal gives. </li>
</ul>
<p>Brug af Tecfidera sammen med alkohol </p>
<p>Indtagelse af mere end en lille mængde (mere end 50 ml) stærk alkohol (mere end 30 volumen%; 
f.eks. spiritus) skal undgås den første time efter indtagelse af Tecfidera, da alkohol kan interagere med 
dette lægemiddel. Dette kan medføre irritation i maven, især hos personer der allerede har 
tilbøjelighed til dette. </p>
<p>Graviditet og amning </p>
<p>Hvis du er gravid eller ammer, har mistanke om, at du er gravid, eller planlægger at blive gravid, skal 
du spørge din læge eller apotekspersonalet til råds, før du tager dette lægemiddel. </p>
<p>Graviditet </p>
<p>Der er begrænset information om virkningen af dette lægemiddel på det ufødte barn, hvis det bruges 
under graviditeten. Tag ikke Tecfidera, hvis du er gravid, medmindre du har drøftet det med din læge, 
og dette lægemiddel er klart nødvendigt for dig. </p>
<p>Amning </p>
<p>Det vides ikke, om det aktive stof i Tecfidera udskilles i modermælk. Din læge vil rådgive dig om, 
hvorvidt du skal stoppe med at amme eller med at tage Tecfidera. Denne overvejelse vil afveje 
fordelen for dit barn ved at amme og fordelen for dig ved behandling. </p>
<p>Trafik- og arbejdssikkerhed </p>
<p>Det forventes ikke, at Tecfidera påvirker din evne til at føre motorkøretøj og betjene maskiner. </p>
<p>Tecfidera indeholder natrium </p>
<p>Dette lægemiddel indeholder mindre end 1 mmol (23 mg) natrium pr. kapsel, dvs. det er i det 
væsentlige natriumfrit. </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take tecfidera"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take tecfidera"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag altid lægemidlet nøjagtigt efter lægens anvisning. Er du i tvivl, så spørg lægen. </p>
<p>Startdosis: 120 mg to gange dagligt. 
Tag denne startdosis de første 7 dage og tag derefter den normale dosis. </p>
<p>Normal dosis: 240 mg to gange dagligt. </p>
<p>Tecfidera er til oral brug. </p>
<p>Hver enterokapsel skal sluges hel med lidt vand. Kapslen må ikke deles, knuses, opløses, suttes eller 
tygges, idet dette kan øge hyppigheden af nogle af bivirkningerne. </p>
<p>Tag Tecfidera sammen med mad - det kan hjælpe med at reducere nogle af de meget almindelige 
bivirkninger (angivet i punkt 4). </p>
<p>Hvis du har taget for meget Tecfidera </p>
<p>Kontakt omgående din læge, hvis du har taget for mange kapsler. Du kan opleve bivirkninger, som 
ligner dem, der beskrives herunder i punkt 4. Hvis du har glemt at tage Tecfidera </p>
<p>Du må ikke tage en dobbeltdosis som erstatning for den glemte dosis. </p>
<p>Du kan tage den glemte dosis, hvis du lader mindst 4 timer gå mellem hver dosis, eller skal du vente til 
næste planlagte dosis. </p>
<p>Spørg lægen eller apotekspersonalet, hvis der er noget, du er i tvivl om. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Dette lægemiddel kan som alle andre lægemidler give bivirkninger, men ikke alle får bivirkninger. </p>
<p>Alvorlige bivirkninger </p>
<p>Tecfidera kan sænke antallet af lymfocytter (en type hvide blodlegemer). Har du et lavt antal hvide 
blodlegemer, kan det øge din risiko for infektion, herunder risikoen for en sjælden hjerneinfektion 
kaldet progressiv multifokal leukoencefalopati (PML). PML kan resultere i svær invaliditet eller død. 
PML er forekommet efter 1 til 5 års behandling, og din læge bør derfor fortsætte med at overvåge dine 
hvide blodlegemer under hele din behandling, og du skal være opmærksom på eventuelle symptomer 
på PML som beskrevet nedenfor. Risikoen for PML kan være højere, hvis du tidligere har taget et 
lægemiddel, der forringer funktionaliteten af din krops immunsystem. </p>
<p>Symptomerne på PML kan ligne et MS-attak. Symptomer kan inkludere ny eller forværret svaghed i 
den ene side af kroppen, klodsethed, synsændringer, ændret tankegang eller hukommelse, forvirring 
eller personlighedsændringer eller tale- og kommunikationsvanskeligheder, der varer længere end 
nogle dage. Hvis du mener, at din MS bliver værre, eller hvis du bemærker nye symptomer under 
behandlingen med Tecfidera, er det derfor meget vigtigt, at du taler med din læge så hurtigt som 
muligt. Du skal også tale med din partner eller omsorgspersoner og fortælle dem om din behandling. 
Der kan opstå symptomer, som du ikke selv er opmærksom på. </p>
<p>→ 
Ring straks til din læge, hvis du får nogle af disse symptomer </p>
<p>Svære overfølsomhedsreaktioner </p>
<p>Hyppigheden af svære overfølsomhedsreaktioner kan ikke estimeres ud fra forhåndenværende data 
(ikke kendt). Rødme i ansigtet eller på kroppen er en meget almindelig bivirkning. Hvis rødmen 
ledsages af et rødt udslæt eller nældefeber, og du samtidig får et eller flere af følgende symptomer:</p>
<ul>
<li>hævelse af ansigt, læber, mund eller tunge (angioødem) </li>
<li>hivende vejrtrækning, vejrtrækningsbesvær eller kortåndethed (dypnø, hypoksi) </li>
<li>svimmelhed eller bevidstløshed (hypotension) </li>
</ul>
<p>kan dette dog være tegn på en svær overfølsomhedsreaktion (anafylaksi). </p>
<p>→ 
Stop med at tage Tecfidera, og ring omgående til en læge </p>
<p>Andre bivirkninger </p>
<p>Meget almindelige (kan forekomme hos flere end 1 ud af 10 personer) 
- rødme i ansigtet eller på kroppen med en varm, eventuel meget varm, brændende fornemmelse 
eller kløe (blussen) 
- løs afføring (diaré) 
- kvalme 
- mavesmerter eller mavekramper </p>
<p>→ 
Hvis du tager lægemidlet sammen med mad, kan det hjælpe med at reducere ovennævnte 
bivirkninger </p>
<p>Stoffer, der kaldes ketoner, som kroppen producerer naturligt, er meget almindelige i urinanalyser 
under Tecfidera-behandling. </p>
<p>Tal med lægen om, hvordan disse bivirkninger skal håndteres. Lægen sætter muligvis din dosis ned. 
Sæt ikke dosis ned, medmindre din læge beder dig om det. </p>
<p>Almindelige (kan forekomme hos op til 1 ud af 10 personer) 
- tarmirritation 
- opkastning 
- dårlig fordøjelse 
- irritation i slimhinden i mave-tarm-kanalen (mavekatar) 
- gener i mave og tarm 
- brændende fornemmelse 
- hedeture, varm fornemmelse 
- hudkløe 
- udslæt 
- lyserøde eller røde pletter på huden 
- hårtab (alopeci) </p>
<p>Bivirkninger, som kan påvises i blod- eller urinprøver 
- lavt antal hvide blodlegemer i blodet. Nedsat antal hvide blodlegemer kan betyde, at din krop er 
dårligere i stand til at bekæmpe en infektion. Såfremt du får en alvorlig infektion (eksempelvis 
lungebetændelse), skal du straks kontakte din læge. 
- protein i urinen 
- forhøjet niveau af leverenzymer (ALAT, ASAT) i blodet </p>
<p>Ikke almindelige (kan forekomme hos op til 1 ud af 100 personer) 
- allergiske reaktioner (overfølsomhed) 
- nedsat antal blodplader </p>
<p>Ikke kendt (hyppighed kan ikke estimeres ud fra forhåndenværende data) 
- leverbetændelse og forhøjede niveauer af leverenzymer (ALAT eller ASAT i kombination med 
bilirubin) 
- herpes zoster (helvedesild) med symptomer såsom blærer, brændende, kløende eller smertende 
hud, typisk på den ene side af overkroppen eller ansigtet og andre symptomer såsom feber og 
svaghed i de tidlige stadier af infektionen, efterfulgt af følelsesløshed, kløe elle røde plamager 
med svære smerter 
- løbende næse (rinorré) </p>
<p>Børn (i alderen 13 år og derover) og unge 
Ovennævnte bivirkninger gælder også for børn og unge. 
En række bivirkninger blev indberettet hyppigere hos børn og unge end hos voksne, f.eks. hovedpine, 
mavesmerter eller -kramper, opkastning, ondt i halsen, hoste og menstruationssmerter. </p>
<p>Indberetning af bivirkninger 
Hvis du oplever bivirkninger, bør du tale med din læge eller apotekspersonalet. Dette gælder også 
mulige bivirkninger, som ikke er medtaget i denne indlægsseddel. Du eller dine pårørende kan også 
indberette bivirkninger direkte til Lægemiddelstyrelsen via det nationale rapporteringssystem anført i 
Appendiks V. Ved at indrapportere bivirkninger kan du hjælpe med at fremskaffe mere information 
om sikkerheden af dette lægemiddel. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store tecfidera"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store tecfidera"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Opbevar lægemidlet utilgængeligt for børn. </p>
<p>Brug ikke lægemidlet efter den udløbsdato, der står på blisterpakningen og kartonen efter “EXP". 
Udløbsdatoen er den sidste dag i den nævnte måned. </p>
<p>Må ikke opbevares ved temperaturer over 30 ºC. 
Opbevar blisterpakningen i den ydre karton for at beskytte mod lys. </p>
<p>Spørg apotekspersonalet, hvordan du skal bortskaffe lægemiddelrester. Af hensyn til miljøet må du 
ikke smide lægemiddelrester i afløbet, toilettet eller skraldespanden. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tecfidera indeholder: </p>
<p>Aktivt stof: dimethylfumarat. 
Tecfidera 120 mg: Hver enterokapsel indeholder 120 mg dimethylfumarat. 
Tecfidera 240 mg: Hver enterokapsel indeholder 240 mg dimethylfumarat. </p>
<p>Øvrige indholdsstoffer: mikrokrystallinsk cellulose, croscarmellosenatrium, talcum, silica, kolloid, 
vandfri, magnesiumstearat, triethylcitrat, methacrylsyre-methylmethacrylat copolymer (1:1), 
methacrylsyre-ethylacrylat copolymer (1:1) dispension 30 %, simeticon, natriumlaurilsulfat, 
polysorbat 80, gelatine, titandioxid (E171), brilliant blue FCF (E133), gul jernoxid (E172), shellac, 
kaliumhydroxid og sort jernoxid (E172). </p>
<p>Udseende og pakningsstørrelser </p>
<p>Tecfidera 120 mg hårde enterokapsler er grønne og hvide og præget med ‘BG-12 120 mg’. De kan fås 
i pakker med 14 kapsler. </p>
<p>Tecfidera 240 mg hårde enterokapsler er grønne og præget med ‘BG-12 240 mg’. De kan fås i pakker 
med 56 eller 168 kapsler. </p>
<p>Ikke alle pakningsstørrelser er nødvendigvis markedsført. </p>
<p>Indehaver af markedsføringstilladelsen </p>
<p>Biogen Netherlands B.V. 
Prins Mauritslaan 1171 LP Badhoevedorp 
Holland </p>
<p>Fremstiller </p>
<p>FUJIFILM Diosynth Biotechnologies Denmark ApS 
Biotek Allé 1 
DK-3400 Hillerød 
Danmark </p>
<p>Biogen Netherlands B.V. 
Prins Mauritslaan 1171 LP Badhoevedorp 
Holland </p>
<p>Hvis du ønsker yderligere oplysninger om dette lægemiddel, skal du henvende dig til den lokale 
repræsentant for indehaveren af markedsføringstilladelsen: </p>
<p>België/Belgique/Belgien 
Biogen Belgium NV/SA 
Tél/Tel: +32 2 2191Lietuva 
Biogen Lithuania UAB 
Tel: +370 5 259 6 
България 
ТП ЕВОФАРМА 
Teл: +359 2 962 12 00<br />
Luxembourg/Luxemburg 
Biogen Belgium NV/SA 
Tél/Tel: +32 2 2191 
Česká republika 
Biogen (Czech Republic) s.r.o. 
Tel: +420 255 706<br />
Magyarország 
Biogen Hungary Kft. 
Tel: + 36 1 899 9 
Danmark 
Biogen (Denmark) A/S 
Tlf: +45 77 41 57<br />
Malta 
Pharma. MT Ltd. 
Tel: +356 21337008<br />
Deutschland 
Biogen GmbH 
Tel: +49 (0) 89 99 6 
Nederland 
Biogen Netherlands B.V. 
Tel: +31 20 542 2 
Eesti 
Biogen Estonia OÜ 
Tel: +372 618 9 
Norge 
Biogen Norway AS 
Tlf: +47 23 40 01 Ελλάδα 
Genesis Pharma SA 
Tηλ: +30 210 8771500<br />
Österreich 
Biogen Austria GmbH 
Tel: +43 1 484 46<br />
España 
Biogen Spain, S.L. 
Tel: +34 91 310 7 
Polska 
Biogen Poland Sp. z o.o. 
Tel: +48 22 351 51<br />
France 
Biogen France SAS 
Tél: +33 (0)1 41 37 95<br />
Portugal 
Biogen Portugal Sociedade Farmacêutica, 
Unipessoal, Lda. 
Tel: +351 21 318 8 
Hrvatska 
Biogen Pharma d.o.o. 
Tel: +385 (0) 1 775 73<br />
România 
Johnson &amp; Johnson Romania S.R.L. 
Tel: +40 21 207 18<br />
Ireland 
Biogen Idec (Ireland) Ltd. 
Tel: +353 (0)1 463 7 
Slovenija 
Biogen Pharma d.o.o. 
Tel: +386 1 511 02 Ísland 
Icepharma hf 
Sími: +354 540 8 
Slovenská republika 
Biogen Slovakia s.r.o. 
Tel: +421 2 323 340<br />
Italia 
Biogen Italia s.r.l. 
Tel: +39 02 5849Suomi/Finland 
Biogen Finland Oy 
Puh/Tel: +358 207 401<br />
Κύπρος 
Genesis Pharma Cyprus Ltd 
Tηλ: +3572 2 765715<br />
Sverige 
Biogen Sweden AB 
Tel: +46 8 594 113<br />
Latvija 
Biogen Latvia SIA 
Tel: +371 68 688 United Kingdom (Northern Ireland) 
Biogen Idec (Ireland) Limited 
Tel: +44 (0) 1628 50 1 </p>
<p>Denne indlægsseddel blev senest ændret {MM ÅÅÅÅ}. </p>
<p>Du kan finde yderligere oplysninger om dette lægemiddel på Det Europæiske Lægemiddelagenturs 
hjemmeside http://www.ema.europa.eu </p>         </div>"""      





                    
Instance: bundlepackageleaflet-en-eb26fa1671149a9a84afe4c1bb85528a
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for tecfidera Package Leaflet for language en"
Description: "ePI document Bundle for tecfidera Package Leaflet for language en"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #en

// Composition
* entry[0].fullUrl = "Composition/composition-en-eb26fa1671149a9a84afe4c1bb85528a"
* entry[0].resource = composition-en-eb26fa1671149a9a84afe4c1bb85528a

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mpeb26fa1671149a9a84afe4c1bb85528a"
* entry[=].resource = mpeb26fa1671149a9a84afe4c1bb85528a
                            
                    
Instance: bundlepackageleaflet-da-eb26fa1671149a9a84afe4c1bb85528a
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for tecfidera Package Leaflet for language da"
Description: "ePI document Bundle for tecfidera Package Leaflet for language da"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #da

// Composition
* entry[0].fullUrl = "Composition/composition-da-eb26fa1671149a9a84afe4c1bb85528a"
* entry[0].resource = composition-da-eb26fa1671149a9a84afe4c1bb85528a

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mpeb26fa1671149a9a84afe4c1bb85528a"
* entry[=].resource = mpeb26fa1671149a9a84afe4c1bb85528a
                            
                    



Instance: mpeb26fa1671149a9a84afe4c1bb85528a
InstanceOf: MedicinalProductDefinitionUvEpi
Title: "Medicinal Product Tecfidera 120 mg gastro-resistant hard capsules"
Description: "Tecfidera 120 mg gastro-resistant hard capsules"
Usage: #inline

 
* identifier[+].system = "http://ema.europa.eu/identifier"
* identifier[=].value = "EU/1/13/837/001"
* type = http://hl7.org/fhir/medicinal-product-type#MedicinalProduct "Medicinal Product"

* domain = http://hl7.org/fhir/medicinal-product-domain#Human "Human use"

* status = http://hl7.org/fhir/publication-status#active "active"



* legalStatusOfSupply = $spor-rms#100000072084 "Medicinal product subject to medical prescription"

* name
  * productName = "Tecfidera 120 mg gastro-resistant hard capsules"
  * type = $spor-productNamePartType-cs#220000000001 "Full name" 
  
  * part[0]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000002 "Invented name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000003 "Scientific name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000004 "Strength part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000005 "Pharmaceutical dose form part"
  
  * usage
    * country = urn:iso:std:iso:3166#EU "EU"
    * jurisdiction = urn:iso:std:iso:3166#EU "EU"
    * language = urn:ietf:bcp:47#en  "en"



RuleSet: eb26fa1671149a9a84afe4c1bb85528aListRuleset

* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* identifier[+].system = "http://spor.ema.europa.eu/v2/medicine-name"
* identifier[=].value = "tecfidera"

* status = #current
* mode = #working

* title = "List of all ePIs associated with tecfidera"

* subject = Reference(mpeb26fa1671149a9a84afe4c1bb85528a)
* subject.extension[0].url = "http://ema.europa.eu/fhir/extension/medicine-name"
* subject.extension[=].valueCoding = $100000000005#tecfidera "tecfidera"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/marketing-authorization-holder"
* subject.extension[=].valueCoding = $100000000005#mah-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/active-substance"
* subject.extension[=].valueCoding = $100000000005#acive-substance-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/domain"
* subject.extension[=].valueCoding = $100000000004#100000000012 "H"

* date = "2015-02-07T13:28:17Z"


* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-en-eb26fa1671149a9a84afe4c1bb85528a) // tecfidera en
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "en"



* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-da-eb26fa1671149a9a84afe4c1bb85528a) // tecfidera da
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "da"




Instance: List-eb26fa1671149a9a84afe4c1bb85528a
InstanceOf: List

* insert eb26fa1671149a9a84afe4c1bb85528aListRuleset
    